Results 141 to 150 of about 585,966 (213)

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy. [PDF]

Eur J Haematol
Oliva S, Molica S.
europepmc   +1 more source

<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study. [PDF]

EJHaem
Haméon C, Houot R, Gyan E, Vallet N, Lachot S, Ganard M, Herault O, De Guibert S, Pastoret C, Dartigeas C.   +9 more
europepmc   +1 more source

Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment

eJHaem
Takafumi Tsushima, Nobue Sato, Yong‐Mei Guo, Hirotaka Nakamura, Kodai Kunisada, Song‐Gi Chi, Kenta Akie, Yuki Takahashi, Saki Nakamura, Kaoru Shimada, Genichiro Ishii, Yosuke Minami, Junichiro Yuda   +12 more
doaj   +1 more source

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]

Future Oncol
Shah BD, Xue M, Furnback W, Yang K.
europepmc   +1 more source

Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe. [PDF]

Cardiooncology
Aurer I, Bulj N, Demirevska L, Dragnić S, Dreisinger M, Goranova-Marinova V, Jakšić O, Lipar L, Rener K, Spassov B, Urošević I, Vukovic V, Žarić E, Zdravković M.   +13 more
europepmc   +1 more source

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report. [PDF]

Cureus
Morinishi CD, Brown CE, Younes R.
europepmc   +1 more source

Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges. [PDF]

Ann Hematol
Wang Y, Zhang Y, Liu J, Jiang Y, Li J, Shi W.   +5 more
europepmc   +1 more source

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia. [PDF]

EJHaem
Heyman B, Choi M, Kipps TJ.
europepmc   +1 more source

Computational hybrid framework integrating clinical-mutation profiling and physics-based simulations to predict structural tolerance of Bruton tyrosine kinase (BTK) and sustained ARQ 531 binding. [PDF]

Curr Res Struct Biol
Khan A, Sawali MA, Shkoor M, Hasssan F, Al-Zoubi RM, Alshabrmi FM, Crovella S, Agouni A.   +7 more
europepmc   +1 more source

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. [PDF]

J Cell Mol Med
Broccoli A, Del Re M, Danesi R, Zinzani PL.   +3 more
europepmc   +1 more source